fbpx
Connect with us

CBD CONDITIONS & TREATMENTS

Treating Health Conditions by Targeting the Endocannabinoid System

Published

on

As we will show, cannabinoids such as Cannabidiol (CBD) can be utilized in the treatment of many difficult ailments. But, to understand how this works, we must first understand the endocannabinoid system of our own body and how its special receptors can be targeted to therapeutic ends by using plant-based compounds.

What is the Endocannabinoid System?

The Endocannabinoid System (ECS) is a physiological system that consists of “receptor cells”. Think of as something like keyholes that can be unlocked by specific keys. This is similar to the synaptic system between neurons, and the neurotransmitters that “unlock” them.

The keys are called “agonists”. The locks are called “receptors”. The agonists unlock the receptors, but they also deliver instructions when they do.

In the ECS, the receptors involved are called CB1 and CB2. And the agonists are endocannabinoids (which just means “internal cannabinoid”).

In the human body, anandamide and 2-Ag. Anandamide are the two key endocannabinoids. They were discovered in the 1960’s (see the work of the Israeli scientist, Raphael Mechoulam) through experimentation with Tetrahydrocannabinol (also commonly known as THC).

Once THC was discovered, everybody wanted to know how it works and if our body is capable of producing the same kind of molecules. Two decades later, we had located and demarcated anandamide (which means “bliss molecule”).

The Endocannabinoid System as a Therapeutic Target

The principle function of the endocannabinoid system (ECS) is to regulate physiological “well-being” at a systemic level. Hence, it can play a role in managing many issues, including:

  • brain disorders,
  • various organ illnesses,
  • musculoskeletal problems,
  • inflammatory and immune system problems

The body regularly produces cannabinoids in regulating these functions. Those internal cannabinoids (or endocannabinoids) work basically like THC or CBD – the most prominent cannabinoids extracted from the cannabis plant.

The main point here is this: cannabinoids are part of our normal evolved functioning physiological system, and they play a key role in maintaining the proper functioning of that system in our daily lives.

But, as with any key physiological system, it doesn’t always work perfectly. And that can lead to various disorders, ailments, symptoms, and complications. But, the good news is, through the use of plant-based cannabinoid treatments, we can treat such issues in the most natural and effective way possible.

But, before we go on to using phyto-cannabinoids to aid the functioning of the ECS, let’s first cover all the areas of our basic systemic health that the ECS regulates:

  • appetite,
  • sleep,
  • mood,
  • digestion,
  • hunger,
  • immune function,
  • motor control,
  • pleasure and reward,
  • fertility and reproduction,
  • memory,
  • pain, and
  • the ability to regulate body temperature.

As you can imagine, with this system functioning at the heart of so many core processes, it holds great promise as a therapeutic target.

Treatment and Therapeutic Promise

Research has shown that it is possible to impact the functioning of the ECS, and such a form of treatment has the potential to aid in combating many health issues. Will such a course of treatment induce a psychoactive “high”? In fact, research has clearly established that proper dosage and administration can produce the desired effects without any such psychoactive consequences.

Importantly, not all of the cannabinoids derived from cannabis induce that type of high. Hence, these compounds have become an intense area of study as potential major treatment solutions for a long list of ailments, including anxiety disorders, mood disorders, Parkinson’s, Huntington’s, multiple sclerosis, neuropathic pain, spinal cord injury, cancer, atherosclerosis, myocardial infarction, hypertension, stroke, glaucoma, osteoporosis, and many more.

Current Pharma Options Targeting the Endocannabinoid System

There are currently few treatments in the pharmaceutical complex that specifically target ECS functioning. But there are some. Sativex (for pain), Cesamet (nausea), and Marinol (nausea and appetite stimulation) are all drugs designed to activate CB1 and CB2 receptor cells.

Cannabidiol (CBD) has been shown to be effective in treating inflammation and stress. That points to applications that include derivative conditions, such as:

  • rheumatoid arthritis,
  • atherosclerosis,
  • diabetes,
  • Alzheimer’s,
  • depression,
  • hypertension, and
  • others

In conclusion, tapping into the body’s ECS functionality offers a tremendous amount of promise for treating a wide variety of ailments and helping people live better and healthier lives.

CBD CONDITIONS & TREATMENTS

WeedMD Inc (OTCMKTS:WDDMF) Rolls Out Its Color Cannabis Brand For Adults

Published

on

WeedMD Inc (OTCMKTS:WDDMF) has announced the launch of its latest brand called Color Cannabis as a premium brand that targets adult users that want high-grade cannabis products.

The new Color Cannabis premium brand features numerous strains of cannabis that are presented in multiple formats. However, they are also developed such that they have a high level of quality as per the expectations of the target consumers. WeedMD’s new brand will only be available to a few distributors and retailers in Canada.

WeedMD plans to have the Color Cannabis-branded products in select stores as well as online availability by Mid-June. The company created the brand with a strategic aim at the diverse preference and tastes of the modern-day cannabis consumer.

“We worked with globally-renowned agency Sid Lee to launch Color – our first adult-use brand,” stated Brett Moon, the Senior Vice President of sales and marketing at WeedMD.

The Color Cannabis brand to mainly focus on a premium user experience

Mr. Moon also noted that Color Cannabis is designed to inspire customers to embrace life and their cannabis experience in personal and unique ways. Aside from being available in the form of dried premium flower, the new WeedMD brand also hosts new product formats over the next few months. Some of those products include gel capsules, oils and pre-rolls and they will be made available with the creation of more consumption formats.

WeedMD CEO Keith Merker stated that Color Cannabis’ goal is to grasp the progressive character, individuality, and imagination of cannabis users. The CEO noted that the goal of the brand is not to tell clients what they will feel but rather to experience the products for themselves. Merker also noted that the Color Cannabis launch represents a key milestone for the company.

WeedMD expects to juggle between the new adult cannabis brand and its medical cannabis pursuits. The company expects to produce about 150,000 kilograms through its 5.2 million square feet production capacity by 2020. The firm also expects to have enough room to handle production for medical cannabis, as well as recreational adult use. It plans to achieve this through its indoor and outdoor growth facilities.

Continue Reading

CBD CONDITIONS & TREATMENTS

HempAmericana Inc. (OTCMKTS:HMPQ) CEO Issues Explains The Company’s Expansion

Published

on

HempAmericana Inc. (OTCMKTS:HMPQ) CEO has issued a letter to shareholders addressing the expansion of the company following string orders.

HempAmericana has begun bottling of full-spectrum CBD distillate

In the letter to shareholders, the CEO indicated that the company has begun establishing growth momentum in its CBD oil production as well as the distribution business. The CEO stated that the company has started bottling of 500 mg as well as 1000 mg full spectrum CBD distillate in its ultramodern CBD production and extraction facility in Augusta Maine.

He added that the company’s initial production is expected to be around 2,000 bottles per day which will be increased gradually to around 8,000 bottles a day to meet demand. Currently, the company has more than 50,000 full spectrum distillate bottles that are ready to be shipped with tens of thousands expected to follow.

HempAmericana is equally bottling a 250 mg potency that is suitable for the CBD-for-pets market. On the high end, the CEO indicated that the company is bottling 2500 mg and 5000 mg but he asserted that they have the potential of replicating any formula.

The CEO further went on to explain that production will be distributed under the company’s proprietary brand “Weed Got Oil.” He added that the company is also pursuing an opportunity in the white label market for the quality full-spectrum distillate CBD Oil. Currently, there are over 400 brands in the CBD market with the majority turning to high capacity producers such as HempAmericana to build product inventory.

Relationship with Eagle Hemp

The company recently announced a relationship with Florida based Eagle Hemp for an initial purchase order as well as the establishment of connections for more orders in the future. The company anticipates strong demand that includes compensation for more production of CBD oil as well as its bottling technology. The first order will bring the company significant revenue input at no associated costs to labeling, bottling, and shipping.

The company’s production facility and lab are currently operating well with two bottling machines in operation. The CEO said that once they distill the interest into purchase orders they will communicate to shareholders.

Continue Reading

CBD CONDITIONS & TREATMENTS

Medmen Enterprises Inc. (OTCMKTS:MMNFF) Expands Its Footprint In California With Acquisition Of One Love

Published

on

MedMen Enterprises Inc. (OTCMKTS:MMNFF) has announced the signing of a definitive agreement for the acquisition of 100% interest in MattnJeremy, Inc. One Love Beach Club.

Acquisition of One Love

The acquisition enhances the company’s California footprint by adding a premier location that is positioned strategically between its LAX and Santa Ana locations. The One Love Beach Club is currently on a run-rate of around $6 million in gross revenue and has an unaudited EBITDA margin of about 29%.

MedMen CEO Adam Bierman stated that they were delighted to have Long Beach on bard as part of the MedMen family as the company continues its growth in the world’s leading cannabis market.

One love was founded back in 2009 and it is located in Long Beach at 2767 E Broadway between Belmont Shore and Downtown some blocks from the beach. Long Beach is located 20 miles from Los Angeles and it is the third largest city in Southern California behind San Diego and Los Angeles with a population of almost half a million.

The city is a prime location that offers attractions, oceanfront hotels, events, recreation activities, shopping, nightly entertainment, restaurants as well as art and culture. According to the Long Beach Convention & Visitors Bureau in 2018 there were approximately 7.9 million visitors who visited the city to attend various events and attractions.

The One Love owner and operator Abrams Family indicated that it had been exciting to have served the Long Beach community for the last ten years adding that they were looking forward to MedMen to continue offering the community with premium cannabis.

Details of the transaction

According to the details of the transaction MedMen is expected to pay around $13 million of which $1 million will be in cash at closing of the deal and $2 million in deferred cash. The rest of the $10 million shall be fulfilled in Class B Subordinate Voting shares. Completion of the transactions depends on regulatory approval by state and local authorities as well as other routine closing conditions. The deal is expected to be closed within 45 days.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories